News


  • 12 November 2012

    Fabrice Egros has been appointed COO, Pharmaceutical Director and board member of NovaMedica, a novel pharmaceutical company

    Fabrice Egros has been appointed COO, Pharmaceutical Director and board member of NovaMedica, a novel pharmaceutical company

    Fabrice Egros was appointed as COO, Pharmaceutical Director and board member of NovaMedica a novel Russian pharmaceutical company, which was established within the frameworks of the joint project between RUSNANO and the American venture fund Domain Associates.

  • 01 October 2012

    Special autumn session for the pharmaceutical business leaders

    Special autumn session for the pharmaceutical business leaders

    Vladimir Gurdus: In order to foster the development of an innovative pharmaceuticals sector in Russia, we need the support of a globally competitive cluster of venture investors in the sector here in Russia.

  • 24 July 2012

    CoDa Therapeutics Completes $49 Million Fund Raising

    CoDa Therapeutics Completes $49 Million Fund Raising

    CoDa Therapeutics, Inc. announced today that it raised an additional NZ$24.5M from Russian investment firm RusnanoMedInvest (“RMI”). This brings the company’s total Series B Round to nearly NZ$49 million following a first close late last year.

  • 24 July 2012

    Domain Associates & RUSNANO announce first joint investment

    Domain Associates & RUSNANO announce first joint investment

    Domain Associates, the Princeton, NJ- and San Diego, CA-based venture capital firm and RusnanoMedInvest (“RMI”, a subsidiary of RUSNANO) today announced their first investment under a joint agreement reached in March. The two will jointly invest nearly $40 million in San Diego, CA-based, CoDa Therapeutics, a Domain portfolio company, along with current investors GBS Ventures (Melbourne, Australia) and BioPacificVentures (Auckland, NZ). 

  • 21 June 2012

    St. Petersburg International Economic Forum

    St. Petersburg International Economic Forum

    Leonid Melamed: Isolated oases of narrowly focused innovation in life sciences are not the way forward for Russia and represent a temporary fix at best – what is needed to drive truly transformational change are fully-integrated life sciences innovation clusters supported by an ecosystem of research and development, finance and other key success factors and specialized skill sets

  • 06 March 2012

    RUSNANO and Domain to Collaborate on Investments in Health Sciences Projects

    RUSNANO and Domain to Collaborate on Investments in Health Sciences Projects

    RUSNANO and Domain Associates, a U.S. venture capital firm specializing in leading-edge life sciences technologies, today announced a partnership that will spur modernization of the Russian healthcare market by bringing next-generation pharmaceuticals, medical devices and diagnostics to Russia.

  • 29 April 2011

    Marinus Pharmaceuticals Issued Patent for Ganaxolone

    Marinus Pharmaceuticals Issued Patent for Ganaxolone

    Marinus Pharmaceuticals, Inc., the leader in development of neurosteroids for central nervous system disorders, today announced that the United States Patent and Trademark Office (USPTO) issued the company Patent Number 7,858,609 entitled, "Solid ganaxolone formulations and methods for the making and use thereof." The patent describes a novel class of small molecules to improve stability and bioavailability of nanoparticulate formulations of ganaxolone and will provide coverage until the end of 2026.  

  • 18 April 2011

    CoDa Therapeutics, Inc. announced that it has raised $19.2 million in a Series B financing.

    CoDa Therapeutics, Inc. announced that it has raised $19.2 million in a Series B financing.

    San Diego, California - April 18, 2011 - CoDa Therapeutics, Inc. announced today that it has raised $19.2 million in a Series B financing.

  • 17 April 2011

    Marinus Pharmaceuticals Announces U.S.  Department of Defense Grant to Study Ganaxolone in Fragile-X Syndrome

    Marinus Pharmaceuticals Announces U.S. Department of Defense Grant to Study Ganaxolone in Fragile-X Syndrome

    Marinus Pharmaceuticals, Inc., the leader in the development of neurosteroids for central nervous system disorders, today announced the award of a $3 million grant by the U.S. Department of Defense to study its lead candidate ganaxolone for the treatment of Fragile-X Syndrome (FXS). Ganaxolone modulates GABA-A ion channels by selective binding to the neurosteroid receptor. Early research suggests that normalizing neurosteroid levels with ganaxolone treatment may eliminate the behavioral symptoms associated with FXS.